New study sheds light on pain and depression
Researchers said that chronic pain is a 'major public health concern' as it affects up to 40% of people in the UK and Europe and is a leading cause of disability.
It has been linked to problems including depression and loneliness, but academics wanted to understand more about the connection, particularly in the period before pain starts.
A team from University College London (UCL) examined 21 years of data from a long-term study tracking the health and wellbeing of patients.
In the new study, published in the journal eClinicalMedicine, experts examined data on more than 7,300 adults in England aged 50 and older.
Half of these went on to suffer pain, including aches and pains of the back, knee, hip or foot, while the others did not.
Researchers found that middle-aged and older adults who experience pain are more likely to have had worsening symptoms of depression up to eight years before the onset of pain.
These symptoms got worse in the years leading up to pain, appeared to peak when the pain was first noticed and remained high in the years after the pain started.
Symptoms of depression were less common, less severe and relatively constant among people who did not suffer pain.
Struggling with feelings of depression, excessive worry, social anxiety, post-traumatic stress or obsessions and compulsions? NHS Talking Therapies can help.
The service is effective, confidential and free.
Your GP can refer you or refer yourself at https://t.co/hLaEBNYcHL pic.twitter.com/VD8EdQsjKP
— NSFT mental health (@NSFTtweets) May 13, 2025
They also found that loneliness increased both in the years before and years after the onset of pain but stayed low and relatively constant among the group who did not suffer pain.
As a result, the researchers suggested that treatment for depression might help to prevent or reduce later aches and pains.
Lead author Dr Mikaela Bloomberg, from UCL's research department of epidemiology and public health, said: 'Pain and depression are known to be linked, with each exacerbating the other. But we don't know about the timing of these related conditions.
'Our study shows that depressive symptoms and loneliness worsen long before pain begins.
'This is important as it suggests the potential for early mental health and social support to reduce or delay later pain.
'Factors such as depression and loneliness can contribute to pain through several mechanisms – by inducing stress, they may increase inflammation, which can lead to pain; they also may increase sensitivity to pain by changing immune responses and by dysregulating our autonomic nervous system, the network of nerves that control unconscious processes such as the 'flight or fight' response.
'Our findings highlight the importance of approaching pain not just from a biological perspective, mental health interventions may be important too.'
The team found that depressive symptoms were most pronounced in people with lower levels of education and among less wealthy patients.
'This study provides further evidence supporting the importance of targeting loneliness and mental health in older people,' the authors wrote.
'Proactive mental health and social support is needed in the decade preceding onset of pain and should be integrated into long-term pain management strategies, particularly for individuals with fewer socioeconomic resources.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
3 hours ago
- Medscape
Younger, Smaller Children Show Less Success With ART
Younger children living with HIV with low BMI for their age were more likely than older children to fail first-line antiretroviral therapy (ART), based on new data from the ODYSSEY trial presented at the International AIDS Society Conference on HIV Science. Although the ODYSSEY trial showed superior efficacy of dolutegravir (DTG)-based treatment than standard of care, data on predictors of treatment failure in children starting ART on DTG-based regimens are limited, wrote James Wyncoll, PhD, medical statistician at University College London, London, England, and colleagues in their abstract. The researchers reviewed data on 381 children who started first-line ART: 189 with DTG and 192 with standard of care. Most of the children (82%) were in Africa, 13% were in Thailand, and 5% were in Europe. At baseline, the median age of the children was 10.5 years, and the median CD4 percentage was 20%. The median BMI-for-age z-score was -0.58, and 19% of the participants met the World Health Organization (WHO) criteria for stage III/IV disease. The researchers considered the predictive values of baseline characteristics across four domains (anthropometrics, HIV indicators, hematology, and demographics) for treatment failure after 96 weeks. Overall, 75 children experienced treatment failure by 96 weeks, including 24 in the DTG group and 51 in the standard-of-care group. Fewer children treated with DTG experienced treatment failure and the risk declined with increasing age, the researchers wrote. However, predictors of treatment failure were not significantly different between treatment groups, they said. In the domain-specific models, after adjustment for weight and trial arm, independent and significant predictors of treatment failure included low BMI-for-age, low CD4%, WHO stage III/IV events, high neutrophils, and care at a location in Africa. In a multivariate analysis, DTG treatment, lower weight, CD4%, ongoing WHO stage III/IV events, and African region remained as significant predictors of treatment failure ( P < .1). Neutrophils were no longer significant after adjustment for ongoing WHO stage III/IV events, and BMI-for-age was no longer a significant predictor after adjustment for CD4% and region. 'The findings of this study can help clinicians by identifying characteristics at ART initiation which predict a child's risk of treatment failure,' Wyncoll told Medscape Medical News . This study provides information on predictors of treatment failure in children starting ART for the first time, including those starting DTG regimens, he said. Outside of clinical trials, adolescents receiving ART reportedly fared worse than younger children, but the current study showed that the risk for treatment failure declined with increasing age, Wyncoll said. 'We think it's likely that in trials, where participants have increased support, adolescents have good responses to treatment, and it is the youngest children who are at highest risk of treatment failure,' he noted. Reasons for greater treatment failure in younger children may include the need for different formulations, as well as the reliance on caregivers to administer the drugs, which can be difficult, he added. Both CD4% and BMI-for-age are previously recognized predictors of treatment failure. Takeaways and Next Steps The study's findings support previous research showing young age as a strong risk factor for treatment failure with ART, Wyncoll told Medscape Medical News. 'Even with early diagnosis and ART, other studies like the EARTH cohort and the LIFE trial show high mortality in the first 2 years of life, especially within the first 6 months,' he said. 'The EARTH study found that an adverse maternal social environment was linked to poorer outcomes and higher treatment failure in young children, emphasizing the need for strong, sustained support for mothers during pregnancy and early life of infants, including emotional and adherence support,' he noted. Screening for and preventing opportunistic infections such as tuberculosis and giving nutritional support is essential to promote treatment success, and baseline CD4 percentage can help identify children at highest risk for treatment failure, he said. The final model in the current study provides the basis for an online risk prediction tool for treatment failure, Wyncoll explained. Clinicians would enter a child's characteristics (such as treatment type, age, CD4%, and BMI for age) at ART initiation. 'Children are currently left behind when we consider novel treatment regimens,' Wyncoll said. 'Our work highlights the need for innovative approaches and more research into improved treatment for vulnerable children, such as different ART delivery methods or enhanced therapeutics,' he added. Although the researchers concluded that predictors of treatment failure for children in the DTG and SOC groups were the same, the findings were limited by the low rates of treatment failure for the children on DTG, Wyncoll told Medscape Medical News . 'Further research is needed using real-world data from children starting dolutegravir to consolidate these findings,' he said. Don't Discount DTG for Children Relatively few studies have examined risk factors for virologic failure in children with HIV, especially those on DTG, said Monica Gandhi, MD, director of the University of California San Francisco (UCSF) Bay Area Center for AIDS Research and professor of medicine at UCSF, in an interview. The current study findings showing a lower CD4 count when initiating ART or ongoing advanced HIV (as represented by the WHO stage III/IV events) or lower weight when starting ART were all risk factors for failure and were not unexpected, Gandhi told Medscape Medical News . 'What was surprising was to see DTG-based ART more associated with failure than standard-of-care (SoC) ART, since DTG is more potent and durable in adults,' she said. The clinical takeaway is to try to start ART in children as soon as possible to avoid low CD4 counts or more advanced HIV on ART, both of which are risk factors for failure, Gandhi said. DTG-based ART should still be the standard of care among children, but additional research is need to determine into what kind of formulations work best younger ages, such as a dispersible tablet for oral suspension, she added.
Yahoo
5 days ago
- Yahoo
Britons smoke an estimated 28.6 billion cigarettes every year, study finds
An estimated 28.6 billion cigarettes are smoked in Britain each year, the equivalent of 78 million a day, according to new analysis. There are particularly high levels of consumption in more disadvantaged areas, with researchers calling for targeted public health efforts to tackle smoking rates. Charities warned the 'staggering figure' is a 'stark reminder of the deadly toll of inaction', and urged the Government to prioritise the Tobacco and Vapes Bill after Parliament's summer recess. The Cancer Research UK study, carried out by experts at University College London (UCL), used monthly Smoking Toolkit Study data from between 2022 and 2024. The analysis estimates adults who smoked consumed an average of 10.4 cigarettes per day, with 5.5% of those smoking more than 20 a day. Average consumption per smoker per year was 528 cigarettes, equating to 28.6 billion per year. Office for National Statistics (ONS) data suggests 11.9% adults in the UK – the equivalent of six million people – smoked in 2023, the lowest proportion since current records began in 2011. However, England could struggle to meet its smokefree target of 5% by 2030 if current trends continue, according to Cancer Research UK, with projections suggesting it may not be met until 2039. The study also highlighted inequalities in cigarette consumption in Britain. People from more deprived backgrounds smoked 11 cigarettes a day on average, compared to those in wealthier areas, who smoked 9.4 per day. Researchers also found people in the North East and Scotland smoked the most – 11.7 each – while people in London and the South West smoked the least, with 8.4 and 9.5 cigarettes respectively. Dr Sarah Jackson, research fellow at UCL's Institute of Epidemiology and Health Care, said bringing down consumption rates can improve public health and also help the environment. 'Tackling smoking is not just about preventing uptake among future generations,' she said. 'Supporting the six million people in the UK who currently smoke cigarettes to quit will have major benefits for public health and for the environment. 'Despite declining smoking rates, over 28 billion cigarettes are still consumed in Great Britain each year, generating up to 140,000 metric tons of toxic, non-biodegradable waste annually. 'Reducing cigarette consumption, particularly in the most affected regions and communities, is critical not only to save lives and narrow health inequalities, but also to protect our environment from one of the most pervasive forms of plastic pollution.' Dr Ian Walker, executive director of policy at Cancer Research UK, said: 'While great strides have been made to bring down smoking rates, we can't afford to be complacent. 'Every week, around 550 million cigarettes are still smoked in Britain – that's enough to fill an Olympic sized swimming pool. It's vital that everyone, wherever they live, can access the support they need to quit smoking for good.' Dr Walker described the Tobacco and Vapes Bill as 'a historic opportunity to help stub out the harms of smoking' but said it is frustrating the the legislation 'isn't progressing through Parliament as quickly as it should be'. The legislation – which cleared the House of Commons in March – will prevent anyone born on or after January 1 2009 from legally smoking if it becomes law. It is set to undergo further scrutiny in the House of Lords. However, around 20 billion cigarettes have been smoked in Britain since the bill was reintroduced in Commons in November last year, according to the analysis. Dr Walker added: 'Tobacco is a toxic product that should have no place in our future, and I urge all parliamentarians to back a smokefree UK and prioritise this Bill when it returns to the House of Lords. 'This world-leading legislation has strong political and public support that can't be ignored.' Reacting to the study, Hazel Cheeseman, chief executive of Action on Smoking and Health (Ash), said: 'Since Parliament last debated the Tobacco and Vapes Bill, an estimated 6.7 billion cigarettes have been smoked in the UK. 'That staggering figure is a stark reminder of the deadly toll of inaction. Every day that passes without this legislation is a day lost in protecting our children from addiction and improving public health. 'We urge the Government to make this Bill a priority immediately after summer recess. The country cannot afford further delay – this is a once-in-a-generation opportunity to create a smokefree future, and it must not be squandered.'
Yahoo
6 days ago
- Yahoo
Britain boosts computing power in $1.3 billion AI drive
LONDON (Reuters) -Britain set out its plan to invest 1 billion pounds ($1.34 billion) in computing infrastructure to drive the development of artificial intelligence, which will increase its public compute capacity 20 fold over the next five years. The race to develop AI is intensifying, with the United States, China and India emerging as front runners, putting pressure on Europe to make up lost ground. British Prime Minister Keir Starmer announced the funding at London Tech Week last month, where he shared the stage with Nvidia's chief executive Jensen Huang. The tech leader said Britain needed to boost its computing infrastructure to deliver the full potential of its leading artificial intelligence research base. The government said on Thursday it would bring together the country's most powerful supercomputers – Isambard-AI based in Bristol and Dawn in Cambridge - in an AI Research Resource (AIRR) system, delivered with partners including Nvidia, HPE, Dell Technologies and Intel. Peter Kyle, Secretary of State for Science, Innovation, and Technology, launched the Isambard supercomputer on Thursday. "Britain has top of the class talent in AI and our plan will put a rocket under our brilliant researchers, scientists, and engineers – giving them the tools they need to make Britain the best place to do their work," he said. University College London researchers are already using the supercomputer to line up pioneering AI tools which could revolutionise cancer screening in the National Health Service, the government said. Using prostate cancer as its initial test case, they are developing one of the first scalable AI models dedicated to medical imaging - using AI to analyse MRI scans and identify patients in need of treatment sooner, it said. Working alongside the AI Research Resource, Britain said it was also setting up a network of National Supercomputing Centres, with the first based in Edinburgh. Meanwhile, Germany wants AI to drive 10% of its economic output by 2030 and make AI an important tool in central fields of research, according to a document seen by Reuters on Tuesday. ($1 = 0.7460 pounds)